{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:20:36Z","timestamp":1790626836549,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.canrad.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T13:20:28Z","timestamp":1532092828000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of FDG PET-CT in the treatment management of Hodgkin lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"A.","family":"Berriolo-Riedinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vander Borght","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"\u00c9deline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.06.001_bib0005","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"(18F)-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0020","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2018.06.001_bib0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1023\/A:1008486928190","article-title":"Whole-body 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease","volume":"9","author":"Bangerter","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0030","first-page":"266","article-title":"Whole-body positron emission tomography using (18F)-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2018.06.001_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using (18F)-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0040","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdh426","article-title":"Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease","volume":"15","author":"Munker","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0045","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2018.06.001_bib0050","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00277-007-0356-9","article-title":"Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi","volume":"86","author":"Rigacci","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdj024","article-title":"scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET\/CT era?","volume":"17","author":"Raanani","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1259\/bjr\/31542964","article-title":"Spleen in haematological malignancies: spectrum of imaging findings","volume":"85","author":"Saboo","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0070","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V91.9.3340","article-title":"Detection of lymphoma in bone marrow by whole-body positron emission tomography","volume":"91","author":"Carr","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejrad.2007.06.014","article-title":"Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET\/CT and bone marrow biopsy","volume":"66","author":"Ribrag","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-009-1377-5","article-title":"FDG PET-CT bone\/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging","volume":"37","author":"Moulin-Romsee","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0085","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0090","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/s00259-009-1306-7","article-title":"Methodological considerations in quantification of oncological FDG-PET studies","volume":"37","author":"Vriens","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0095","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00259-005-1784-1","article-title":"PET\/CT with intravenous contrast can be used for PET attenuation correction in cancer patients","volume":"32","author":"Berthelsen","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R","article-title":"The significance of mediastinal involvement in early stage Hodgkin's disease","volume":"42","author":"Mauch","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.001_bib0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/1097-0142(19840115)53:2<324::AID-CNCR2820530225>3.0.CO;2-E","article-title":"Prognostic significance of mediastinal mass in adult Hodgkin's disease","volume":"53","author":"Schomberg","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.001_bib0110","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1200\/JCO.2001.19.5.1388","article-title":"Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance","volume":"19","author":"Gobbi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0115","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/cncr.20568","article-title":"The clinical value of tumor burden at diagnosis in Hodgkin lymphoma","volume":"101","author":"Gobbi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.001_bib0120","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-0142(19880415)61:8<1719::AID-CNCR2820610834>3.0.CO;2-A","article-title":"Tumor burden as themost important prognostic factor in early stage Hodgkin's disease. Relations toother prognostic factors and implications for choice of treatment","volume":"61","author":"Specht","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.001_bib0125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/annonc\/mds649","article-title":"Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer","volume":"24","author":"Park","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-011-1357-2","article-title":"Clinical significance of metabolic tumor volume by PET\/CT in stages II and III ofdiffuse large B cell lymphoma without extranodal site involvement","volume":"91","author":"Song","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0135","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0140","first-page":"s125","article-title":"Prognosis value of baseline total metabolic tumor volume in advanced Hodgkin lymphoma: Ancillary study of AHL2011 LYSA trial","volume":"41","author":"Kanoun","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Imaging subcommittee of International Harmonization Project in lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging subcommittee of International Harmonization Project in lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0155","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0160","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0170","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0175","first-page":"20","article-title":"FDG-PET imaging for Hodgkin lymphoma: current use and future applications","volume":"12","author":"Kostakoglu","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","article-title":"The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale","volume":"99","author":"Gallamini","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2018.06.001_bib0185","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim (18F)-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0190","first-page":"55","article-title":"Recommendations to stage and asses the response to therapy of lymphomas with (18F)-FDG PET-CT","volume":"40","author":"Barrington","year":"2016","journal-title":"Med Nucl"},{"key":"10.1016\/j.canrad.2018.06.001_bib0195","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0200","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0205","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0210","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Initial results of US intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB\/Alliance 50604)","volume":"126","author":"Straus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0215","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0220","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","article-title":"Early chemotherapy intensification with BEACOPP in advanced stage Hodgkin lymphoma patients with a interim PET positive after two ABVD courses","volume":"152","author":"Gallamini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0225","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0230","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0235","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2009.25.4367","article-title":"Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy","volume":"28","author":"Cerci","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0240","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdq549","article-title":"End of treatment but not interim PET scan predicts outcome in non-bulky limited-stage Hodgkin's lymphoma","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2967\/jnumed.107.039867","article-title":"(18F)-FDG-PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review","volume":"49","author":"Terasawa","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2018.06.001_bib0250","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood.V98.10.2930","article-title":"Thoracic positron emission tomography using (18F)-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease","volume":"98","author":"Weihrauch","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0255","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1080\/1042819042000223813","article-title":"Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses","volume":"45","author":"Panizo","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2018.06.001_bib0260","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0265","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00259-016-3390-9","article-title":"Diagnostic accuracy of FDG PET-CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)","volume":"43","author":"Fallanca","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.canrad.2018.06.001_bib0270","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.06.001_bib0275","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","article-title":"Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced stage Hodgkin lymphoma","volume":"112","author":"Kobe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0280","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0285","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canrad.2018.06.001_bib0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","article-title":"Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma aftercompletion of first-line therapy","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0295","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/08880018.2015.1085934","article-title":"Outcome of Hodgkin lymphoma patients with a post treatment (18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) negative residual mass: systematic review and meta-analysis","volume":"32","author":"Adams","year":"2015","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0300","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.23688","article-title":"Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma","volume":"89","author":"El-Galaly","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.314.7077.343a","article-title":"Follow-up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records","volume":"314","author":"Radford","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.canrad.2018.06.001_bib0310","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1200\/JCO.1997.15.3.1123","article-title":"Detection of relapse in early stage Hodgkin's disease: role of routine follow-up studies","volume":"15","author":"Torrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1148\/radiol.2511081296","article-title":"cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults","volume":"251","author":"Sodickson","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.canrad.2018.06.001_bib0320","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1002\/cncr.25240","article-title":"Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.06.001_bib0325","first-page":"47","article-title":"Follow-up of patients with classical Hodgin lymphoma after treatment--novel evidence and dilemmas. Literature review","volume":"138","author":"Milunovic","year":"2016","journal-title":"Lijec Vjesn"},{"key":"10.1016\/j.canrad.2018.06.001_bib0330","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","article-title":"Role of functional imaging in the management of lymphoma","volume":"29","author":"Cheson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0335","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/annonc\/mdp519","article-title":"Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG PET\/CT for follow-up?","volume":"21","author":"Petrausch","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0340","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-006-0167-4","article-title":"Unsuspected FDG-PET findings in the follow-up of patients with lymphoma","volume":"86","author":"Sonet","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0345","first-page":"CD010533","article-title":"Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma","volume":"1","author":"Sickinger","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2018.06.001_bib0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-015-0360-6","article-title":"Hodgkin lymphoma: the changing role of radiation therapy in early stage disease-the role of functional imaging","volume":"16","author":"Iberri","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0355","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved-node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.06.001_bib0360","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int Radiat Oncol Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818301239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:28:43Z","timestamp":1761136123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818301239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1278321818301239"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.06.001","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of FDG PET-CT in the treatment management of Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}